Disparities in filled opioid use disorder prescriptions linked to COVID-19 pandemic

The COVID-19 pandemic was a likely cause for worsened disparities in buprenorphine and naltrexone access for opioid use disorder among minority groups compared with white patients, per a study published in JAMA Network Open.
“Despite some progress in [medications for opioid use disorder] use, pre-pandemic evidence suggested that it was associated with frequent exposure to high out-of-pocket costs and inequitable distribution, with greater access for white individuals and communities with primarily white populations,” Thuy Nguyen, PhD, of the University of Michigan’s School of

The COVID-19 pandemic was a likely cause for worsened disparities in buprenorphine and naltrexone access for opioid use disorder among minority groups compared with white patients, per a study published in JAMA Network Open.
“Despite some progress in [medications for opioid use disorder] use, pre-pandemic evidence suggested that it was associated with frequent exposure to high out-of-pocket costs and inequitable distribution, with greater access for white individuals and communities with primarily white populations,” Thuy Nguyen, PhD, of the University of Michigan’s School of